Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of AK130 + ivonescimab in advanced biliary tract malignancies
CTR20250630Phase 2Active
- Sponsor
- Akeso, Inc.
- Start
- Apr 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of lucorafusp alfa, ivonescimab in biliary cancer, sponsored by Akeso, Inc.. Started Apr 2025; status: active.
02
Drugs
lucorafusp alfaivonescimab
03
Conditions
biliary cancer
Beyond the preview
Go deeper on CTR20250630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250630.